Efficacy of triple therapy and exploration of factors influencing treatment benefit in unresectable hepatocellular carcinoma: a meta-analysis
Frontiers in Oncology · 11.11.2026 · 16
DOI: 10.3389/fonc.2026.1965453 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Frontiers in Oncology, online erschienen am 11.11.2026. Verfasst von Shiyan Zhang und 7 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This meta-analysis evaluated the efficacy of transarterial chemoembolization (TACE) combined with anti-vascular endothelial growth factor (VEGF)/tyrosine kinase inhibitors (TKIs) and programed cell death protein 1 (PD-1)/programed cell death protein ligand 1 (PD-L1) inhibitors in unresectable hepatocellular carcinoma (uHCC), as well as the relevant influencing factors.
Methods
Four databases were searched through August 2026 for studies comparing TACE plus anti-VEGF/TKIs and PD-1/PD-L1 inhibitors with other regimens in uHCC. Random-effects models were used to pool hazard ratios (HRs) with corresponding 95% confidence intervals (95%CIs). The outcome s of this study were progression-free survival (PFS) and overall survival (OS). Exploratory subgroup analyses were performed based on patient and tumor characteristics.
Results
A total of 31 studies comprising over 8,900 patients were included. The triple therapy group was associated with significantly improved PFS (HR = 0.49, 95%CI [0.43, 0.55], p<0.001) and OS (HR = 0.45, 95%CI [0.39, 0.53], p<0.001) compared with the control group. Exploratory subgroup analyses suggested that younger patients (<50–65 years old), those with an Eastern Cooperative Oncology Group performance status of 0, patients with hepatitis B virus infection, patients without portal vein tumor thrombus, extrahepatic metastasis, or vascular invasion, and those with up-to-seven criteria>7 (especially the largest tumor size>10 cm) might have a better survival with the triple regimen.
Conclusion
Triple therapy with TACE, anti-VEGF/TKIs, and PD-1/PD-L1 inhibitors was associated with significantly improved prognosis in uHCC.
Zitieren
APA
Zhang, S., Feng, X., Zhang, Q., Ji, J., Wang, L., Jiang, T., Chen, Y., & Jin, Q. (2026). Efficacy of triple therapy and exploration of factors influencing treatment benefit in unresectable hepatocellular carcinoma: a meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1965453
Vancouver
Zhang S, Feng X, Zhang Q, Ji J, Wang L, Jiang T, et al. Efficacy of triple therapy and exploration of factors influencing treatment benefit in unresectable hepatocellular carcinoma: a meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1965453
BibTeX
@article{Zhang2026,
author = {Zhang, Shiyan and Feng, Xiaoling and Zhang, Qiufeng and Ji, Jiani and Wang, Lei and Jiang, Ting and Chen, Yixia and Jin, Qiong},
title = {Efficacy of triple therapy and exploration of factors influencing treatment benefit in unresectable hepatocellular carcinoma: a meta-analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1965453}
}
EUVIMED